(Total Views: 70)
Posted On: 12/23/2024 11:56:19 AM
Post# of 43997
Big news: Cell Source ( $CLCS ) Presents Potential Breakthrough in the Development of Off-the-Shelf CAR-T Cell Therapy at American Society of Hematology Annual Meeting
https://finance.yahoo.com/news/cell-source-pr...00616.html
The research showcased how the company's proprietary Veto Cell technology can overcome one of the most critical barriers in allogeneic cell therapy - natural killer (NK) cell-mediated rejection. This innovation brings the field closer to realizing off-the-shelf CAR-T therapies, which can be safer, less costly and more scalable than existing allogeneic CAR-T.
https://finance.yahoo.com/news/cell-source-pr...00616.html
The research showcased how the company's proprietary Veto Cell technology can overcome one of the most critical barriers in allogeneic cell therapy - natural killer (NK) cell-mediated rejection. This innovation brings the field closer to realizing off-the-shelf CAR-T therapies, which can be safer, less costly and more scalable than existing allogeneic CAR-T.
(0)
(0)
